Jefferies Financial Group Reaffirms “Buy” Rating for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating restated by research analysts at Jefferies Financial Group in a research note issued to investors on Friday, Digital Look reports. They presently have a GBX 2,025 price target on the stock. Jefferies Financial Group’s price target points to a potential upside of 26.33% from the company’s previous close.

Other analysts have also recently issued reports about the company. Berenberg Bank boosted their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Citigroup lifted their price target on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of GBX 2,085.83.

Hikma Pharmaceuticals Stock Up 0.8%

Shares of Hikma Pharmaceuticals stock opened at GBX 1,603 on Friday. Hikma Pharmaceuticals has a 1 year low of GBX 1,187 and a 1 year high of GBX 1,865. The firm has a market cap of £3.32 billion, a price-to-earnings ratio of 9.11, a PEG ratio of 2.38 and a beta of 0.66. The company has a 50-day moving average of GBX 1,602.90 and a 200 day moving average of GBX 1,478.29. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27.

Insider Buying and Selling at Hikma Pharmaceuticals

In related news, insider Tobias Hestler bought 7,500 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were bought at an average cost of GBX 1,648 per share, for a total transaction of £123,600. 22.26% of the stock is owned by corporate insiders.

Hikma Pharmaceuticals News Summary

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Jefferies reaffirmed its “buy” rating and set a GBX 2,025 price target, implying meaningful upside from recent trading levels. The recommendation reinforces confidence in Hikma’s outlook and is likely supporting investor sentiment. Jefferies reaffirms buy rating and price target
• Positive Sentiment: Rebecca Hall has been appointed chief financial officer and executive director. Hall joins from ViiV Healthcare, where she was a senior finance leader. Her appointment may be viewed positively because of her pharmaceutical-sector experience and could strengthen Hikma’s financial and strategic execution. Hikma appoints Rebecca Hall as CFO
• Neutral Sentiment: Current CFO Khalid Nabilsi is stepping down as Hall becomes his successor. The transition is a notable governance and management change, but the available reports do not indicate operational disruption or a change to Hikma’s financial guidance. Hikma CFO transition

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.